<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738891</url>
  </required_header>
  <id_info>
    <org_study_id>ZA18-003</org_study_id>
    <nct_id>NCT03738891</nct_id>
  </id_info>
  <brief_title>CoolSculpting and EMS for the Abdomen</brief_title>
  <acronym>ECA</acronym>
  <official_title>A Feasibility Study to Evaluate Electromagnetic Muscle Stimulation and CoolSculpting for Abdominal Contouring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeltiq Aesthetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeltiq Aesthetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the use of Electromagnetic Muscle Stimulation as an adjunctive treatment to
      CoolSculpting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint in relation to adverse events</measure>
    <time_frame>Final post treatment 1 day visit</time_frame>
    <description>Measurement of device- or procedure-related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness endpoint gauged by photographs</measure>
    <time_frame>Final post treatment 1 day visit</time_frame>
    <description>Comparison of pre-treatment- and 12-week post-final treatment photographs to assess visible changes in the abdomen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-D imaging</measure>
    <time_frame>Final post treatment 1 day visit</time_frame>
    <description>Reduction in abdominal circumference as measured by 3-Dimensional imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Final post treatment 1 day visit</time_frame>
    <description>Subject- graded GAIS at 12-week post-final treatment follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Body Fat Disorder</condition>
  <arm_group>
    <arm_group_label>Fat Reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatments are designed to see if the fat can be reduced in the abdomen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The ZELTIQ System</intervention_name>
    <description>The CoolSculpting machine will be used to perform the treatments.</description>
    <arm_group_label>Fat Reduction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male and female subjects &gt; 22 years of age and ≤65 years of age.

          -  Subject has not had weight change exceeding 5% of body weight in the preceding month.

          -  Subject agrees to maintain her weight (i.e., within 5%) by not making any major
             changes in diet or exercise routine during the course of the study.

          -  Subject agrees to refrain from any new abdominal training exercises during the course
             of the study.

          -  BMI ≤ 30 kg/m2 as determined at screening.

          -  Abdominal skin fold thickness 2.0 to 5.0 cm, as measured by caliper below umbilicus.

          -  Subject has read and signed a written informed consent form.

        Exclusion Criteria

          -  Subject has had a surgical procedure(s) in the area of intended treatment.

          -  Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy)
             in the area of intended treatment.

          -  Subject has had a non-invasive fat reduction, body contouring and/or skin tightening
             procedure in the area of intended treatment within the past 12 months.

          -  Subject has numbness, tingling or other altered sensation in the treatment area.

          -  Subject needs to administer, or has a known history of subcutaneous injections into
             the area of intended treatment (e.g., heparin, insulin) within the past month.

          -  Subject has not had an intrauterine contraceptive device inserted or removed within
             the past month.

          -  Subject has a known history of cryoglobulinemia, cold urticaria, cold agglutinin
             disease, or paroxysmal cold hemoglobinuria

          -  Subject has a known history of Raynaud's disease, or any known condition with a
             response to cold exposure that limits blood flow to the skin.

          -  Subject has a history of bleeding disorder or is taking any medication that in the
             Investigator's opinion may increase the subject's risk of bruising.

          -  Subject has known sensitivity or allergy to isopropyl alcohol and propylene glycol, or
             latex.

          -  Subject is taking or has taken diet pills or supplements within the past month.

          -  Subject has any dermatological conditions, such as moderate to excessive skin laxity,
             or scars in the location of the treatment sites, that may interfere with the treatment
             or evaluation (stretch marks is not an exclusion).

          -  Subject has a metal implant or active implanted device such as a pacemaker,
             defibrillator, or drug delivery system.

          -  Subject has been involved in any type of abdominal muscle training program within the
             previous 6 months.

          -  Subject has pulmonary insufficiency.

          -  Subject has a cardiac disorder.

          -  Subject has a malignant tumor.

          -  Subject has been diagnosed with epilepsy.

          -  Subject currently has a fever.

          -  Subject is pregnant or intending to become pregnant during the study period (in the
             next 9 months).

          -  Subject is lactating or has been lactating in the past 6 months.

          -  Subject is unable or unwilling to comply with the study requirements.

          -  Subject is currently enrolled in a clinical study of any other investigational drug or
             device.

          -  Any other condition or laboratory value that would, in the professional opinion of the
             Investigator, potentially affect the subject's response or the integrity of the data
             or would pose an unacceptable risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerrie Jiang, NP</last_name>
    <role>Study Director</role>
    <affiliation>Zeltiq Aesthetics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tonia N Madere</last_name>
    <phone>925-474-2537</phone>
    <email>tonia.madere@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Marina Plastic Surgery</name>
      <address>
        <city>Marina Del Rey</city>
        <state>California</state>
        <zip>90292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovation Research Center</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lan La</last_name>
      <phone>925-474-2501</phone>
      <email>clinicalstudy@pleasantonirc.com</email>
    </contact>
    <investigator>
      <last_name>Eric Bachelor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of Northern California</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aesthetic Solutions, P.A.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

